AstraZeneca To Fight NICE Knockback For Tagrisso In England
Following NICE’s rejection last week for Tagrisso, AstraZeneca argues that the health technology appraisal body was wrong not to take the company’s real-world data into account when considering whether the lung cancer drug should be granted “end of life” status.
You may also be interested in...
Health technology assessment body NICE has published two final guidance documents that cover the use of AstraZeneca’s drug at different points in the treatment pathway for locally advanced or metastatic EGFR-positive non-small cell lung cancer.
Tagrisso, Lynparza and Imfinzi are enjoying stellar sales growth which is unlikely to slow down any time soon.
Pfizer and AstraZeneca were seeking National Health Service funding for the same indication for their respective lung cancer drugs. With "responsible pricing" after an initial rejection, Pfizer prevailed.